際際滷

際際滷Share a Scribd company logo

Vit o cv2013

O
Oliver Vit

Oliver Vit is a Swiss citizen with over 20 years of experience in the pharmaceutical industry. He holds a Bachelor's degree in Chemistry from New York University and postgraduate degrees from the University of London and University of Oxford. Vit currently works as a Senior Life Cycle Project Manager at Actelion Pharmaceuticals Ltd in Basel, Switzerland, where he has led multi-disciplinary teams and managed drug development programs from early research through regulatory approval and launch. He is fluent in English, French, and German with conversational Spanish.

Convert to study guideBETA

Transform any presentation into a summarized study guide, highlighting the most important points and key insights.

1 of 18
Download to read offline
Oliver Vit Lohnhofgaesslein 16 CH-4051 Basel Switzerland mobile: +41 79 346 38 40 olivervit@hotmail.com Personal attributes Male Single Citizenship Born 27 th June 1972 Basel, Switzerland Polyvalent Switzerland Czech Republic Analytical Persuasive Innovative Pragmatic World Service USA Determined Authority Athletic Personal experience & achievements United Kingdom Postgraduate diploma Switzerland Strategy & Innovation 12 years Actelion Pharmaceuticals Ltd Master of Science Global Business & Science Affairs Drug Development Senior Life Cycle Project Manager Honors with distinction San Francisco 7 years Childhood New York 3 years Bachelors degree Chemistry New Jersey Self sponsored, 13 years overland/sea travels Community College High school Early childhood
Education 2010 2011 University of Oxford Sa誰d Business School Postgraduate Diploma Strategy & Innovation 2008 2009 University of London Queen Marys School of Medicine & Dentistry Master of Science in Drug Development Graduated with distinction 1993 1996 New York University Bachelors Degree in Chemistry Employment history Actelion Pharmaceuticals, Ltd Basel, Switzerland 2007 2012 Global Business & Science Affairs Senior Life Cycle Project Manager In this position I authored protocols, developed target product profiles, co-authored clinical development plans, and conducted independent market research in parallel to grappling with moving targets and maintaining both team focus & morale. Working with no direct reports and within a matrix environment composed of members from almost every other internal department and potentially representatives of external partners, my professional function was to lead & support the Life Cycle Team as it drove programs forward through to the market respecting the limits set by the characteristics of each compound, the supporting fundamental sciences, the competitive environment, patent protection, the annual budget and Actelion's corporate vision. GB&SA was charged with the task of strategically linking apt, innovative research to both the needs of future prescribers and the continued growth of Actelion by bringing novel agents which address unmet medical needs robustly to the market in the timeliest manner. 2003 - 2006 Technical Operations Clinical Trials Supplies Manager Upon joining Actelion, CTS management was a nascent competence and my remit extended well beyond negotiating cost efficient, timely packaging & delivery of QP released supplies globally in support of Actelion's growing number of clinical trials. In addition to liaising between the clinical teams and the 3rd party providers, I was charged with multiple tasks in building the CTS unit, e.g. writing the first SOPs, establishing global distribution networks, creating & implementing the first interdepartmental software which was used to monitor CTS stocks globally, initiate, track & trace shipments and record compliant returns & destruction prior to study closure. I was also responsible for the recruitment and training of new employees who eventually replaced the previous team under my guidance.
Almedica HPS AG Reinach, Switzerland 2001 - 2003 Client Services Global Project Manager As my first professional experience in Switzerland this position made use of my ability to speak multiple languages, consult, pitch & negotiate contracts with potential clients in the pharmaceutical industry, identify & satisfy customer needs, understand & coordinate internally across all departments & functions to ensure both GMP compliance and the timely internal release of packaged materials within budget, and liaise with both the US head office and UK affiliate. Products & candidates Compound Mode of action Route of Indication Class administration Anti- L/T channel blocker oral capsule Hypertension hypertensive Angina pectoris Cadazolid Inhibition of topoisomerase & oral suspension Clostridium difficile infection protein synthesis Ponesimod Multiple sclerosis Plaque psoriasis Sequestration of T-cells in Other lymph nodes and Peyers oral tablet Ponesimod f/u patches Auto-immune disorders Olesoxime Mitochondrial permeability oral liquid filled Amyotrophic Lateral Sclerosis transition pore modulation capsugel Spinal muscular atrophy Zavesca速 Inhibition of glucosylceramide oral capsule Type I Gaucher (miglustat) synthase Niemann-Pick Type C In my role as a Senior Life Cycle Project Manager I led the multi-disciplined life cycle teams for cadazolid, olesoxime and the ponesimod follow-up compound while having provided assistance to the life cycle teams charged with the development of ponesimod, an anti-hypertensive and Zavesca速 (miglustat). This cross-functional leadership role encompasses: setting & adhering to the annual budget, drafting, finalizing & adapting the integrated project plans, execution of development strategy, identification of development hurdles & market opportunities, generation, review & updating of most critical core documentation, setting & achieving project goals, matrix management, challenge & defense of corporate strategy. I have worked with multiple drug candidates & marketed products from a wide array of molecular targets employing different formulations across numerous indications in development stages: Phase I, II, III, and IV. In particular both the olesoxime and ponesimod projects were managed while in partnerships with both Trophos SA and Hoffmann-La Roche Ltd respectively.
Recent professional experience & group achievements MARKETING DISCOVERY Full scale development DEVELOPMENT Launch Phase III Commercialisation Lead optimisation Target selection Concept testing HTS Preclinical testing Phase II Subm ission Launch key Candidate selection Safety testing markets First approval process Phase I Hit Lead First dose in First submission indication Entry into Human Anti-hypertensive Cadazolid Ponesimod Ponesimod f/u Olesoxime Zavesca速 Protocols * Pre-IND meetings Investigators brochures * o Neurology division Clinical development plans * o Dermatology division Target product profiles * o Division of special Competitive intelligence briefings * pathogens & transplant Business case development Clinical Trial Applications Alliance management o EU/EEA Risk management plans o Israel Expert panel meetings IND filings Annual budgets o Neurology division o Division of special New indication research * pathogens & transplant INN filings Patent filings *authorship
Corporate deliverables inclusive of academic theses (sample non-confidential files available upon request) 2011 Actelion Pharmaceuticals Ltd Proof-of-concept protocols Target product profiles Investigators brochure Sad Business School, Oxford University FINAL 2011 DipSI Postgraduate Diploma in Strategy & Innovation Thesis Oliver Vit CV.pdf Actelion Pharmaceuticals Ltd, the Quest for a 2nd Partner 2010 Actelion Pharmaceuticals Ltd Crohn's Disease Competitive intelligence reports Pharmascape CV.pdf Crohns Disease, Pharmascape Psoriasis, Pharmascape Psoriasis Pharmascape CV.pdf 2009 Queen Marys School of Medicine & Dentistry, University of London Master of Science in Drug Development FINAL 2009 MSc Oral MS Therapy, the Coming Revolution Thesis Oliver Vit CV.pdf Actelion Pharmaceuticals Ltd Multiple Sclerosis, Clinical Development Plan
Languages Fluent Conversational & English Written French German Spanish Rudimentary Portuguese Recent conferences & trainings 2011 Imperial College London Immunology for Physicians & Clinicians 2010 European Committee for Treatment & Research in Multiple Sclerosis (ECTRIMS) 2009 International Society for Pharmacoeconomics & Outcomes Research (ISPOR) 12 th annual conference
References Actelion Pharmaceuticals Ltd Isaac Kobrin, MD (retired) Senior Vice President Chief Medical Officer itzikkob@gmail.com +41 79 372 68 66 Michael Scherz, PhD Vice President Life Cycle Leader michael.scherz@actelion.com +41 61 565 65 94 Jasper Dingemanse, PhD Vice President Head of Clinical Pharmacology jasper.dingemanse@actelion.com +41 61 565 64 63 Novartis Pharma AG Vaclav Sulista, PhD PU Head TRD Services vaclav.sulista@novartis.com +41 61 696 13 21 Bayer HealthCare Pharmaceuticals Malcolm Allison Vice President Global Team Leader PH malcolm.allison@bayer.com +49 175 309 27 50 Stanford University Jed Black, MD Consulting professor Actelion Vice President (former) Therapeutic Area Head Sleep Disorders black.jed@gmail.com +1 650 464-9129 (GMT-8 h) University of London Atholl Johnston, PhD Queen Marys School of Medicine & Dentistry Professor of Clinical Pharmacology William Harvey Institute Head of Postgraduate Taught Courses Clinical Pharmacology a.johnston@qmul.ac.uk +44 20 7882 3404
Current attestation
Vit o cv2013
Additional attestations
Vit o cv2013
Vit o cv2013
Vit o cv2013
Vit o cv2013
Vit o cv2013
Diplomas
Vit o cv2013
Vit o cv2013

More Related Content

Vit o cv2013

  • 1. Oliver Vit Lohnhofgaesslein 16 CH-4051 Basel Switzerland mobile: +41 79 346 38 40 olivervit@hotmail.com Personal attributes Male Single Citizenship Born 27 th June 1972 Basel, Switzerland Polyvalent Switzerland Czech Republic Analytical Persuasive Innovative Pragmatic World Service USA Determined Authority Athletic Personal experience & achievements United Kingdom Postgraduate diploma Switzerland Strategy & Innovation 12 years Actelion Pharmaceuticals Ltd Master of Science Global Business & Science Affairs Drug Development Senior Life Cycle Project Manager Honors with distinction San Francisco 7 years Childhood New York 3 years Bachelors degree Chemistry New Jersey Self sponsored, 13 years overland/sea travels Community College High school Early childhood
  • 2. Education 2010 2011 University of Oxford Sa誰d Business School Postgraduate Diploma Strategy & Innovation 2008 2009 University of London Queen Marys School of Medicine & Dentistry Master of Science in Drug Development Graduated with distinction 1993 1996 New York University Bachelors Degree in Chemistry Employment history Actelion Pharmaceuticals, Ltd Basel, Switzerland 2007 2012 Global Business & Science Affairs Senior Life Cycle Project Manager In this position I authored protocols, developed target product profiles, co-authored clinical development plans, and conducted independent market research in parallel to grappling with moving targets and maintaining both team focus & morale. Working with no direct reports and within a matrix environment composed of members from almost every other internal department and potentially representatives of external partners, my professional function was to lead & support the Life Cycle Team as it drove programs forward through to the market respecting the limits set by the characteristics of each compound, the supporting fundamental sciences, the competitive environment, patent protection, the annual budget and Actelion's corporate vision. GB&SA was charged with the task of strategically linking apt, innovative research to both the needs of future prescribers and the continued growth of Actelion by bringing novel agents which address unmet medical needs robustly to the market in the timeliest manner. 2003 - 2006 Technical Operations Clinical Trials Supplies Manager Upon joining Actelion, CTS management was a nascent competence and my remit extended well beyond negotiating cost efficient, timely packaging & delivery of QP released supplies globally in support of Actelion's growing number of clinical trials. In addition to liaising between the clinical teams and the 3rd party providers, I was charged with multiple tasks in building the CTS unit, e.g. writing the first SOPs, establishing global distribution networks, creating & implementing the first interdepartmental software which was used to monitor CTS stocks globally, initiate, track & trace shipments and record compliant returns & destruction prior to study closure. I was also responsible for the recruitment and training of new employees who eventually replaced the previous team under my guidance.
  • 3. Almedica HPS AG Reinach, Switzerland 2001 - 2003 Client Services Global Project Manager As my first professional experience in Switzerland this position made use of my ability to speak multiple languages, consult, pitch & negotiate contracts with potential clients in the pharmaceutical industry, identify & satisfy customer needs, understand & coordinate internally across all departments & functions to ensure both GMP compliance and the timely internal release of packaged materials within budget, and liaise with both the US head office and UK affiliate. Products & candidates Compound Mode of action Route of Indication Class administration Anti- L/T channel blocker oral capsule Hypertension hypertensive Angina pectoris Cadazolid Inhibition of topoisomerase & oral suspension Clostridium difficile infection protein synthesis Ponesimod Multiple sclerosis Plaque psoriasis Sequestration of T-cells in Other lymph nodes and Peyers oral tablet Ponesimod f/u patches Auto-immune disorders Olesoxime Mitochondrial permeability oral liquid filled Amyotrophic Lateral Sclerosis transition pore modulation capsugel Spinal muscular atrophy Zavesca速 Inhibition of glucosylceramide oral capsule Type I Gaucher (miglustat) synthase Niemann-Pick Type C In my role as a Senior Life Cycle Project Manager I led the multi-disciplined life cycle teams for cadazolid, olesoxime and the ponesimod follow-up compound while having provided assistance to the life cycle teams charged with the development of ponesimod, an anti-hypertensive and Zavesca速 (miglustat). This cross-functional leadership role encompasses: setting & adhering to the annual budget, drafting, finalizing & adapting the integrated project plans, execution of development strategy, identification of development hurdles & market opportunities, generation, review & updating of most critical core documentation, setting & achieving project goals, matrix management, challenge & defense of corporate strategy. I have worked with multiple drug candidates & marketed products from a wide array of molecular targets employing different formulations across numerous indications in development stages: Phase I, II, III, and IV. In particular both the olesoxime and ponesimod projects were managed while in partnerships with both Trophos SA and Hoffmann-La Roche Ltd respectively.
  • 4. Recent professional experience & group achievements MARKETING DISCOVERY Full scale development DEVELOPMENT Launch Phase III Commercialisation Lead optimisation Target selection Concept testing HTS Preclinical testing Phase II Subm ission Launch key Candidate selection Safety testing markets First approval process Phase I Hit Lead First dose in First submission indication Entry into Human Anti-hypertensive Cadazolid Ponesimod Ponesimod f/u Olesoxime Zavesca速 Protocols * Pre-IND meetings Investigators brochures * o Neurology division Clinical development plans * o Dermatology division Target product profiles * o Division of special Competitive intelligence briefings * pathogens & transplant Business case development Clinical Trial Applications Alliance management o EU/EEA Risk management plans o Israel Expert panel meetings IND filings Annual budgets o Neurology division o Division of special New indication research * pathogens & transplant INN filings Patent filings *authorship
  • 5. Corporate deliverables inclusive of academic theses (sample non-confidential files available upon request) 2011 Actelion Pharmaceuticals Ltd Proof-of-concept protocols Target product profiles Investigators brochure Sad Business School, Oxford University FINAL 2011 DipSI Postgraduate Diploma in Strategy & Innovation Thesis Oliver Vit CV.pdf Actelion Pharmaceuticals Ltd, the Quest for a 2nd Partner 2010 Actelion Pharmaceuticals Ltd Crohn's Disease Competitive intelligence reports Pharmascape CV.pdf Crohns Disease, Pharmascape Psoriasis, Pharmascape Psoriasis Pharmascape CV.pdf 2009 Queen Marys School of Medicine & Dentistry, University of London Master of Science in Drug Development FINAL 2009 MSc Oral MS Therapy, the Coming Revolution Thesis Oliver Vit CV.pdf Actelion Pharmaceuticals Ltd Multiple Sclerosis, Clinical Development Plan
  • 6. Languages Fluent Conversational & English Written French German Spanish Rudimentary Portuguese Recent conferences & trainings 2011 Imperial College London Immunology for Physicians & Clinicians 2010 European Committee for Treatment & Research in Multiple Sclerosis (ECTRIMS) 2009 International Society for Pharmacoeconomics & Outcomes Research (ISPOR) 12 th annual conference
  • 7. References Actelion Pharmaceuticals Ltd Isaac Kobrin, MD (retired) Senior Vice President Chief Medical Officer itzikkob@gmail.com +41 79 372 68 66 Michael Scherz, PhD Vice President Life Cycle Leader michael.scherz@actelion.com +41 61 565 65 94 Jasper Dingemanse, PhD Vice President Head of Clinical Pharmacology jasper.dingemanse@actelion.com +41 61 565 64 63 Novartis Pharma AG Vaclav Sulista, PhD PU Head TRD Services vaclav.sulista@novartis.com +41 61 696 13 21 Bayer HealthCare Pharmaceuticals Malcolm Allison Vice President Global Team Leader PH malcolm.allison@bayer.com +49 175 309 27 50 Stanford University Jed Black, MD Consulting professor Actelion Vice President (former) Therapeutic Area Head Sleep Disorders black.jed@gmail.com +1 650 464-9129 (GMT-8 h) University of London Atholl Johnston, PhD Queen Marys School of Medicine & Dentistry Professor of Clinical Pharmacology William Harvey Institute Head of Postgraduate Taught Courses Clinical Pharmacology a.johnston@qmul.ac.uk +44 20 7882 3404